Open Access

PET/CT and PET/MRI in ophthalmic oncology (Review)

  • Authors:
    • Maria S. Kalemaki
    • Apostolos H. Karantanas
    • Dimitris Exarchos
    • Efstathios T. Detorakis
    • Odysseas Zoras
    • Kostas Marias
    • Corina Millo
    • Ulas Bagci
    • Ioannis Pallikaris
    • Andreas Stratis
    • Ioannis Karatzanis
    • Kostas Perisinakis
    • Pavlos Koutentakis
    • Georgios A. Kontadakis
    • Demetrios A. Spandidos
    • Aristidis Tsatsakis
    • Georgios Z. Papadakis
  • View Affiliations

  • Published online on: January 3, 2020     https://doi.org/10.3892/ijo.2020.4955
  • Pages: 417-429
  • Copyright: © Kalemaki et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Orbital and ocular anatomy is quite complex, consisting of several tissues, which can give rise to both benign and malignant tumors, while several primary neoplasms can metastasize to the orbital and ocular space. Early detection, accurate staging and re‑staging, efficient monitoring of treatment response, non‑invasive differentiation between benign and malignant lesions, and accurate planning of external radiation treatment, are of utmost importance for the optimal and individualized management of ophthalmic oncology patients. Addressing these challenges requires the employment of several diagnostic imaging techniques, such as high‑definition digital fundus photography, ultrasound imaging, optical coherence tomography, optical coherence tomography (OCT)‑angiography, computed tomography (CT) and magnetic resonance imaging (MRI). In recent years, technological advances have enabled the development of hybrid positron emission tomography (PET)/CT and PET/MRI systems, setting new standards in cancer diagnosis and treatment. The capability of simultaneously targeting several cancer‑related biochemical procedures using positron emitting‑radiopharmaceuticals, while morphologically characterizing lesions by CT or MRI, together with the intrinsic quantitative capabilities of PET‑imaging, provide incremental diagnostic information, enabling accurate, highly efficient and personalized treatment strategies. Aim of the current review is to discuss the current applications of hybrid PET/CT and PET/MRI imaging in the management of patients presenting with the most commonly encountered orbital and ocular tumors.

1. Introduction

The orbital and ocular space consists of several anatomical structures (Fig. 1) out of which various tumors may arise, while orbital or ocular metastases from several primary malignancies can be encountered, often being the first sign of cancer dissemination. Prompt diagnosis, accurate staging and restaging, and effective assessment of treatment response are crucial for designing patient-tailored therapeutic strategies. Cross-sectional imaging with conventional modalities [computed tomography (CT) and magnetic resonance imaging (MRI)] has being widely used for the management of these lesions. However, in recent years, with the emergence of advanced hybrid imaging techniques using positron emission tomography (PET)/CT and PET/MRI systems, as the corner-stone of diagnostic imaging for oncologic purposes, an emerging role of these modalities has been recorded in the management of patients with orbital and ocular tumors. This review focuses on current applications and future directions of PET/CT and PET/MRI in ophthalmic oncology.

PET is a diagnostic imaging technique that enables targeting, visualization and quantification of biochemical processes at the cellular and sub-cellular level, via the three-dimensional (3-D) reconstruction of the bio-distribution of several molecules radiolabeled with positron-emitting isotopes. Hybrid PET/CT systems combine the functional information provided by the PET component with the structural information obtained from CT, enabling attenuation correction of PET-images, accurate anatomic localization of the distribution of the PET-tracer and morphological characterization of lesions, leading to increased diagnostic performance (1). Moreover, the employment of contrast-enhanced CT as part of PET/CT studies, can provide additional diagnostic information, further improving the diagnostic capabilities of the modality (2).

Hybrid PET/MRI systems hold promise for superior diagnostic capabilities for oncologic applications, since MRI is an ionizing-radiation free method, that can be used for the MR-based attenuation correction of the PET-images, while offering superior soft-tissue contrast resolution, together with a broad spectrum of imaging applications such as dynamic contrast enhanced MRI (DCE-MRI), MR-spectroscopy (MRS) and diffusion weighted imaging (DWI), enabling the acquisition of both anatomical and functional information (3). In recent years, technological advancements have led to the development of clinical simultaneous PET/MRI systems, allowing superior spatial registration of PET and MR images and enabling temporal correlation between PET and MRI data, opening a broad new horizon of diagnostic capabilities (4).

The PET-radiopharmaceuticals discussed in the current review are summarized in Table I. 18Fluoride-fludeoxyglucose (18F-FDG) is a glucose analogue radiolabeled with fluorine-18 (18F), reflecting glucose consumption and therefore, whole-body 18FDG PET/CT studies can produce a whole-body metabolic map of the patient (5). Increased glucose uptake is one of the major metabolic features encountered in cancer cells, making 18F-FDG the most widely employed PET-tracer for oncologic purposes (1,6-8). However, abnormally increased 18F-FDG activity is not cancer-specific, since various benign processes, such as adenomas, or infectious and inflammatory lesions exhibit hyper-metabolism (9-13). 18F-sodium fluoride (18F-NaF) is a bone seeking PET-radiopharmaceutical, which can effectively target both osteoblastic and osteolytic processes, leading to increased bone surface area being exposed to the blood flow (14). The favorable 18F-NaF pharmacokinetics, the superior spatial resolution of PET, together with the inherent quantitative capabilities of PET-imaging and the capability for morphologic characterization of lesions by the CT, render 18F-NaF PET/CT a powerful diagnostic tool for oncologic skeletal imaging (15-18). 68Ga-DOTA-compounds are somatostatin (SST) analogs, radiolabeled with the positron emitting isotope gallium-68 (68Ga) through the chelator 1,4,7,10-tetraazacyclododecane-1, 4,7,10-tetraacetic acid (DOTA) (18). The employment of these compounds enables highly efficient targeting of lesions which are characterized by cell-surface over-expression of SST receptors (SSTRs), such as neuroendocrine tumors (NETs), for which PET/CT imaging with 68Ga-DOTA-compounds is evolving as the imaging standard of reference (19-33).

Table I

PET-radiopharmaceuticals employed for PET/CT studies in patients with orbital and ocular tumors.

Table I

PET-radiopharmaceuticals employed for PET/CT studies in patients with orbital and ocular tumors.

Feature 18F-FDG 18F-NaF 68Ga-DOTA- compounds 18F-fluorocholine (18F-FCH) 11C-methionine Methyl (11C-MET) Alpha-[11C] -L-Tryptophan (11C-AMT)
Half-life110 min110 min68 min110 min20 min20 min
Synthesis requirementsCyclotronCyclotronIn-house generatorCyclotronCyclotronCyclotron
Molecular targetMetabolic activityBone remodelingSSTRs cell surface overexpressionCell membrane synthesisAmino acid transportTryptophan metabolism
Orbital or ocular tumorLymphoma, uveal melanoma, retinoblastoma conjunctival melanoma, sebaceous carcinoma, squamous cell carcinoma, optic nerve glioma, ocular and orbital metastases, inflammatory orbital pseudotumor, fibrous dysplasiaFibrous dysplasiaOcular and orbital metastases from neuroendocrine tumors (NETs)Optic nerve glioma

[i] SSTR, somatostatin receptor; 18F-FDG, 18fluoride-fludeoxyglucose; 18F-NaF, 18F-sodium fluoride.

2. Orbital lymphoma and ocular adnexal lymphoma

Orbital lymphoma (OL) and ocular adnexal lymphoma (OAL), are lypmphoproliferative malignancies, involving the orbit, the eyelid, the conjunctiva, the lacrimal gland, or a combination of these structures (34). OL is the most common primary malignant tumor of the orbits among adults (35), whereas OAL accounts for 55% of orbital malignancies among adults and represents 1-2% of non-Hodgkin’s lymphoma (NHL) cases and 8% of extra-nodal mucosa-associated lymphoid tissue (MALT) lymphomas (36,37). In the majority of cases, OALs mainly arise from the lacrimal gland and the conjunctiva, with 7-24% of patients presenting with bilateral involvement (36). OL and OAL can either be primary malignancies or metastases from systemic disease. Histologically, the most common type of OAL is MALT lymphoma, which is a low-grade B-cell NHL (35). Once the diagnosis of OL or OAL has been established, accurate disease staging is of utmost importance for optimal patient management. Whole-body PET/CT post 18F-FDG administration has evolved as the standard of care for initial disease staging and post-treatment evaluation, rendering OL and OAL the main orbital and ocular tumors, for which PET/CT is routinely employed (35) (Figs. 2-4). Low-grade MALT lymphomas may exhibit low hyper-metabolic activity and therefore low-level 18F-FDG uptake, or may even present false negative findings on 18F-FDG PET/CT. However, even for low-grade OLs and OALs, 18F-FDG PET/CT has been proven to be highly sensitive for accurate disease staging by detecting distant metastases, missed on conventional imaging (35,36).

In a retrospective study of 11 patients with an established diagnosis of OAL who underwent whole-body 18F-FDG PET scans at initial staging, Valenzuela et al reported that 18F-FDG PET exhibited higher sensitivity in detecting systematic extra-nodal disease compared to conventional imaging with CT, leading to disease upstaging and significantly affecting patient management; however, the efficacy of the modality in detecting orbital lesions was limited, mainly due to the small size of the lesions and physiologic 18F-FDG uptake by the extraocular muscles (38). English and Sullivan, in a series of 34 patients who also underwent 18F-FDG PET at initial staging, confirmed the enhanced performance of the modality in accurate disease staging, by detecting sites of systemic disease missed on CT, and therefore, significantly altering management strategies; their study also confirmed the limited performance of 18F-FDG PET in comparison to CT in detecting local OAL lesions (37).

However, the advent of hybrid PET/CT technology had a direct impact on OL and OAL detection performance. Roeet al, in a series of 4 patients with biopsy-proven OAL, demonstrated that hybrid 18F-FDG PET/CT was capable of detecting the orbital tumor in 3 patients (75%), while revealing systematic involvement in 2 of the 4 patients (50%) (39). Sugaet al reported that in a patient with orbital MALT lymphoma, 18F-FDG PET/CT was able to identify a small lesion in the contralateral orbit, which had been missed on MR-imaging, and an unexpected metastatic gastric lesion, indicating the increased efficacy of the method in accurate disease staging (40). Furthermore, post-treatment 18F-FDG PET/CT scans revealed progressive regression and finally the disappearance of 18F-FDG activity at disease sites, suggesting the utility of the modality for monitoring treatment response (40). Several other studies have confirmed the usefulness of 18F-FDG PET/CT for the initial staging and assessment of treatment response in patients with OLs and OALs (41-43).

Fujiet al, in a recent series of 9 patients with histologically proven OAL [diffuse large B-cell lymphoma, MALT, follicular lymphoma, natural killer (NK)/T-cell lymphoma, lymphoplas-macytic lymphoma, Hodgkin’s lymphoma (HL)] who underwent pre- and post- treatment 18F-FDG PET/CT investigated the utility of the modality in assessing treatment response (44). 18F-FDG uptake was assessed by means of maximum standard-ized uptake value (SUVmax), and a decrease was recorded in 8 out of the 9 patients post-treatment, while in 7 patients there was a complete metabolic response from the first post-treatment scan, which was in accordance with the clinical condition of the patients during the follow-up period. Only in one patient there was a false-negative conjunctival lesion on 18F-FDG PET/CT, indicating that the usefulness of the modality may be affected by the histological type and the anatomic location.

3. Uveal melanoma

Uveal melanoma (UM) (Fig. 5) is the most common primary intraocular malignancy among adults, and most frequently arises from the choroid (85% of cases) (36,45). Singhet al, in a systematic review including 4,070 patients with primary UM in the USA over a 36-year period from 1973 to 2008, reported a mean age-adjusted incidence of 5.1 per million of population (95% CI, 4.8-5.3), a predilection for the Caucasian population (97.8% of cases) and an unaltered 5-year survival rate of 81.6% (46). Tumor size, an age >60 years, intense tumor pigmentation and localization in the anterior uvea have been shown to indicate a poor prognosis (36). Although distant metastases can occur to the lungs, bones and the central nervous system, UM presents a unique metastatic pattern to the liver, as the main site for disease dissemination (36,45,47). Therefore, accurate disease staging is critical for guiding decision-making in patients diagnosed with UM.

In an early study by Reddyet al, including a cohort of 50 patients with untreated choroidal melanomas [American Joint Cancer Committee (AJCC); T1:18 patients, 36%; T2:24 patients, 48%; T3:8 patients, 16%], 18F-FDG PET/CT failed to detect any of the AJCC-T1 tumors, while increased 18F-FDG activity (SUVmax >2.5) was observed in 33 and 75% of AJCC-T2 and AJCC-T3 choroidal melanomas, respectively (48). According to these findings, it was suggested that 18F-FDG PET/CT most likely cannot differentiate small UMs from suspicious nevi, and does not seem to be superior over standard clinical evaluation with ophthalmoscopy, fluorescein angiography and ophthalmic ultrasonography (US) in the detection of primary choroidal melanomas. Fingeret al, in a series of 14 patients with choroidal melanomas (AJCC-T2, 1 patient; AJCC-T3, 13 patients), reported that the one T2 tumor and 10 out of the 13 (77%) T3 tumors demonstrated elevated 18F-FDG uptake (SUVmax >2.5) with the highest SUV value (9.0) observed in the tumor which was largest in size (49). Furthermore, they reported a positive association between SUV values with known clinical, pathological and US characteristics related to increased metastatic potential, indicating possible prognostic value of 18F-FDG uptake observed on PET/CT in the setting of UM (49).

In a cohort of 7 patients with choroidal melanoma, Matsuoet al explored the association between 18F-FDG avidity and the clinicopathological characteristics of the tumors. 18F-FDG PET/CT detected the primary tumor in 5 out of 7 patients, concluding that large nodular choroidal melanomas can be effectively identified by 18F-FDG PET/CT, in contrast to diffusely infiltrating choroidal melanomas without nodular formation, which proved to be 18F-FDG-negative (50). However, all distant liver and bony metastases in 2 of the patients in the cohort were effectively targeted with 18F-FDG PET/CT, suggesting the employment of the modality for disease staging. Furthermore, a positive association was reported between tumor size, as defined by histopathological measurements and 18F-FDG uptake, as determined by SUVmax (50). McCannelet al, in a retrospective study including 37 patients with primary choroidal melanomas, reported significant association between 18F-FDG positivity of the tumors (SUVmax >2.5) with larger tumor size and with chromosome 3 loss, which is a known risk factor related with increased metastatic potential of choroidal melanomas (51). This data indicated that apart from tumor size, 18F-FDG positivity may be associated with molecular features of UMs and that 18F-FDG avidity holds promise to serve as an independent prognostic biomarker for patients with UM.

Papastefanouet al, in a retrospective study of 76 patients diagnosed with UM who underwent pre-operative 18F-FDG PET/CT scans, reported 18F-FDG positivity (SUVmax >2.5) in 92% of the tumors (52). In addition, 94% of patients with chromosome 3 monosomy exhibited 18F-FDG avidity (SUVmax >2.5), whereas patients with abnormalities (gains) in chromosome 8, which is also associated with a poor prognosis in UM did not exhibit significantly higher 18F-FDG activity. Moreover, increased tumor size and AJCC tumor-node-metastases (TNM) prognostic groups were positively associated with 18F-FDG uptake, as determined by SUVmax, further implying the prognostic application of 18F-FDG PET/CT imaging in the setting of patients with UM (52).

However, the main indication for the employment of 18F-FDG PET/CT in the work-up of patients with UM is the detection of regional and distant metastasis. Kurliet al reported 100% sensitivity and 100% specificity of 18F-FDG PET/CT in detecting liver metastases compared to 12.5% sensitivity of liver function tests (LFTs). Furthermore, 18F-FDG PET/CT significantly contributed to the detection of osseous extra-hepatic metastatic lesions, implying the application of this technique for disease staging at the time of initial diagnosis as well as for follow-up purposes (53). In a large retrospective series of 333 patients with UM, who underwent whole-body 18F-FDG PET/CT studies for staging purposes at the time of initial diagnosis, Fretonet al confirmed the value of the modality as a screening tool for initial staging (54). All 18F-FDG-positive liver lesions observed on PET/CT were subsequently confirmed as metastases via biopsies, indicating 100% positive predictive value (PPV), providing significant advantages over anatomic imaging techniques, which exhibit a higher rate of false-positive liver findings. Furthermore, 18F-FDG PET/CT enabled the detection of extra-hepatic disease sites missed on blood tests or conventional imaging, and revealed synchronous second primary malignancies in 3.3% (95% CI: 0.9-5.5) of the study population, significantly affecting patient management (54).

However, Strobelet al, in a retrospective study of 13 patients with UM, questioned the usefulness of 18F-FDG PET/CT in UM staging, since 16 out of 27 liver lesions (59%) were 18F-FDG-negative, all of which were detected by anatomic imaging with CT or MRI (55). Furthermore, liver metastases from UM demonstrated significantly (P<0.001) lower 18F-FDG uptake in terms of SUVmax in comparison to liver metastases from cutaneous melanoma, although histological analysis did not reveal any difference in glucose transporter-1 (GLUT-1) expression between UM and CM liver metastases (55). In accordance with the findings of the study by Strobelet al (55), Orcurtoet al reported the superiority of MRI over 18F-FDG PET/CT in detecting small metastatic liver lesions in patients with UM (56). However, Orcurtoet al (56) observed that during chemotherapy, 18F-FDG activity in liver lesions with a stable size on MRI, exhibited a significantly decreased lesion-to-liver SUV ratio, while enlarging lesions on MRI exhibited an increased lesion-to-liver SUV ratio. These data suggest the application of 18F-FDG PET/CT in the early assessment of treatment response (56).

4. Retinoblastoma

Retinoblastoma (RB) is a malignant tumor of the retina originating from precursor cells of the retinal neuroepithelium (36). RB is the most common intraocular tumor in childhood, with 95% of patients being diagnosed by the age of 5 (57). RB can be encountered either in a hereditary (40%) or in a sporadic form (60%), with patients with hereditary RB presenting with an increased risk of developing intracranial primitive neuroecto-dermal tumor (PNET), most frequently pineoblastomas (58-60). The combination of unilateral or bilateral hereditary RB with an intracranial PNET is termed trilateral RB, which is often associated with a poor prognosis due to spinal dissemination (61). RBs typically present with leukocoria, while proptosis, pain, redness and swelling can be common RB manifestations (62).

Radhakrishnanet al, in a prospective evaluation of the role of 18F-FDG PET/CT in staging and assessment of the response to neoadjuvant chemotherapy, demonstrated that intraocular RB did not take up the radiotracer, in contrast to the 18F-FDG avidity of extraocular RBs (63). Furthermore, no significant difference was revealed between staging with CT or MRI and staging based on 18F-FDG PET/CT findings. However, the detection of 18F-FDG uptake by the optic nerve at the baseline PET/CT study was strongly associated with poor event-free survival (EFS) and overall survival (OS), indicating a strong prognostic value, in comparison to patients with no 18F-FDG uptake by the optic nerve. In addition, a complete or partial response to neoadjuvant chemotherapy assessed by 18F-FDG PET/CT was associated with an improved EFS and OS, further supporting the prognostic value of the modality (63).

5. Conjunctival melanoma

Conjunctival melanoma (CM) is a relatively rare, yet potentially lethal malignancy with an increasing incidence rate (64). Folberget al reported that approximately 75% of CMs typically arise from primary acquired melanosis (PAM), with 9-25% of patients with CM presenting local or systematic spread with lymph node (LN) involvement (65,66). In a retrospective cross-sectional study including 85 patients with primary CM, aiming to elucidate the metastatic pattern of this neoplasm, Tuomaala and Kivelä demonstrated that initial regional LN and systematic metastasis were equally encountered, with LN infiltration being associated with a better prognosis (67). Major metastatic sites are the lungs, the liver, the gastrointestinal track and the central nervous system (68).

18F-FDG PET/CT has been employed for staging purposes in patients with CM. Kurliet al investigated 14 patients with CM (13 patients with T3 tumors, 1 patient with T4 tumor), who were evaluated with whole body 18F-FDG PET/CT scans for the detection of metastatic disease (68). Seven of these patients were scanned with 18F-FDG PET/CT at initial diagnosis and 7 were imaged post-treatment (surgical removal with adjuvant cryotherapy and/or chemotherapy). The study concluded that 18F-FDG PET/CT failed to reveal local, regional or systemic disease in any of the 13 patients with diffuse, multifocal T3 CM, either at initial diagnosis or post-treatment. On the contrary, the post-treatment 18F-FDG PET/CT scan revealed widespread metastases in the nasal fossa, liver, pleural space, mediastinal lymph nodes, lungs, peritoneal cavity, lumbar spine and right supraclavicular lymph node in the patient with T4 CM. Based on these data, Kurliet al suggested the limited application of 18F-FDG PET/CT at the initial staging of patients with CM, with potential usefulness for follow-up and re-staging purposes (68).

Damianet al reported the positive contribution of 18F-FDG PET/CT in the effective management of a patient with CM, by successfully detecting the primary ocular lesion and an infiltrated preauricular node, and by excluding other LN involvement or systemic dissemination of the disease (66). Tsaiet al described the usefulness of 18F-FDG PET/CT in revealing CM as a second primary neoplasm, in a patient with lymphocytic lymphoma/chronic lymphocytic leukemia (CLL) and nasal cavity carcinoma (69). Given these data, further studies are required to explore the potential usefulness of 18F-FDG PET/CT in the management of CM.

6. Sebaceous carcinoma

Sebaceous carcinoma (SebCa) is a rare type of cancer with a low incidence rate (0.11 to 0.65 cases/100,000 individuals/year) and a higher prevalence in the female population (70,71). With the face being the most common anatomical region for SebCa due to the abundance of sebaceous glands, it is usually presented as a nodule or diffuse thickening of the eyelids (71). Although the upper lid and the palpebral conjunctiva are the most common sites, SebCa may also arise in the bulbar conjunctiva and the caruncle (71). Eyelid SebCa can often be misdiagnosed both clinically and pathologically (72). Typically, there is a delay in the diagnosis associated with a higher recurrence rate following surgical excision, ranging from 18 to 19.4% (71,72). Distant and nodal metastases have been associated with eyelid SebCa in 3-8 and 8-18% of cases, respectively (71).

In a series of 15 patients with biopsy-proven periorbital tumors Baeket al, reported that in the subset of patients (5 out of 15) with SebCa of the upper eyelid 18F-FDG PET/CT successfully detected all cases with regional LN involvement, even when contrast-enhanced CT was falsely negative (73). Krishnaet al reported the employment of 18F-FDG PET/CT in successfully staging 2 patients with ocular SebCa, critically contributing to optimal patient management, guiding the decision to preserve the eye and implying the application of the modality in accurate staging of ocular and non-ocular SebCas (74). Furthermore, follow-up in patients with SebCa can be facilitated with 18F-FDG PET/CT. Ishiguroet al reported the detection of a colon adenocarcinoma 42 months following the surgical removal of a left upper eyelid SebCa, in a patient with Muir-Torre syndrome, which is characterized by the presence of at least one sebaceous skin tumor (75). Thus, 18F-FDG PET/CT is of value for staging and restaging purposes in patients with SebCa.

7. Squamous cell carcinoma

Squamous cell carcinoma (SCC) is a type of skin cancer which manifests as a scaled, indurated, keratinized or ulcerated raised nodule or plaque, which is most commonly encountered in the lower eyelid and medial canthus, with an incidence rate 3-fold higher in males than in females (71). SCC arises from abnormal keratinocyte proliferation and either emerges for the first time without any previous predisposition or in sites of pre-existing actinic or solar keratosis (71). The clinical presentation of SCC may vary from erythematous patches to large ulcerated lesions. The 5-year recurrence rate ranges from 2.4 to 36.9% with regional LN involvement at 25% of cases, and distant metastases in 6.2% of cases, with the most common regional metastatic sites being the parotid, the preauricular and the submandibular nodes (76,77). Periocular SCC is highly metastatic in the case of delayed treatment, invading orbital and intracranial structures and leading to considerably increased mortality and morbidity (78,79).

18F-FDG PET/CT has been reported to be an effective tool for the detection of distant metastases in patients with recurrent head and neck SCCs (HNSCCs). In a series of 82 patients with histologically confirmed HNSCCs, Yiet al reported that whole-body 18F-FDG PET/CT correctly identified distant metastases in 12 of 14 patients and their absence in 57 of 68 patients, exhibiting sensitivity, specificity, accuracy, PPVs and negative predictive values (NPVs) of 86% (95% CI, 57-98%), 84% (72-91%), 84% (74-91%), 52% (30-73%) and 97% (88-99%), respectively (80). Literature on the employment of 18F-FDG PET/CT in the work-up of patients with eyelid or conjunctival SCC is rather limited. Linet al reported high 18F-FDG avidity (SUVmax: 8) by a biopsy proven left bulbar conjunctiva SCC, in a patient with previous history of endometrial lymphoma (81). Abdelmaliket al reported a patient with a biopsy-proven left orbital SCC, which was intensely 18F-FDG avid in the pre-treatment PET/CT scan (82). Furthermore, several retromandibular, mediastinal and abdominal LNs demonstrated increased 18F-FDG activity, with only the retromandibular being metastatic and the remainder being inflammatory, highlighting the limitations of the modality in cancer staging, since both malignant and inflammatory processes exhibit elevated 18F-FDG uptake (82). Therefore, based on the existing literature, further studies are required to justify the usefulness of 18F-FDG PET/CT in the setting of periocular SCC.

8. Rhabdomyosarcoma

Rhabdomyosarcoma (RMS) is the most common mesenchymal tumor in childhood accounting for approximately 4-5% of all pediatric cancers, with orbits being the commonest site in the head and neck (36,83). Orbital RMS usually presents as a unilateral rapidly progressive mass, leading to proptosis or globe displacement, while eyelid edema, hemorrhage, pain, vision impairment, blepharoptosis, conjunctival edema and inflammatory signs consist non-specific RMS manifestations. RMS of the orbits is an aggressive, life-threatening malignancy with high potential to infiltrate adjacent tissues, while metastatic dissemination can occur to the lungs, bones, bone marrow and LNs (83). Therefore, accurate initial staging and restaging is critical for the optimal and individualized patient management.

Normanet al, in a systematic review including 272 patients with RMS, with orbits being the primary tumor site in at least 13 cases (not all included studies provided information on the location of the primary tumor), investigated the role of 18F-FDG PET and 18F-FDG PET/CT in the management of childhood RMS (84). They reported that 18F-FDG PET and 18F-FDG PET/CT had been consistently superior over conventional imaging (contrast-enhanced CT, standard MRI, technetium-99m bone scintigraphy) at the initial RMS staging, since LN involvement and distant metastases were determined with higher accuracy. Furthermore, the management strategy was altered based on 18F-FDG PET and 18F-FDG PET/CT findings in 7/40 (17.5%) RMS patients (not all the included studies provided information on this outcome) (84). However, the role of 18F-FDG PET/CT as a prognostic indicator of the outcome in patients with RMS, is controversial (85). Moreover, patients and particularly pediatric patients with RMS may benefit from 18F-FDG PET/MRI, which promises more accurate locoregional staging and follow-up evaluation (36,86).

9. Optic nerve glioma

Optic nerve glioma (ONG), also known as optic pathway glioma (OPG), is the most common primary optic nerve tumor, accounting for approximately 1% of all intracranial tumors. ONG is divided into two types: A low-grade benign form and an aggressive highly malignant form. Benign ONGs are slow-growing tumors, which are mostly encountered in children and are often associated with neurofibromatosis type 1 (NF-1). Bilateral ONGs are almost pathognomonic for NF-1. ONGs in pediatric patients usually present with painless proptosis, decreased visual acuity, visual fields, or color vision, while compression effects can cause hypothalamic symptoms or obstructive hydrocephalus due to the compression of the third ventricle and central retinal vein occlusion (CRVO) because of the compression of the central retinal vein. The aggressive form of ONGs is mainly encountered among adults and consists a life-threatening malignancy with poor prognosis. ONGs among adults are rapidly-growing neoplasms, which present with acute vision loss bilaterally due to the involvement of the optic chiasm (36,87-89).

Miyamotoet al first reported intense 18F-FDG uptake by an ONG in an adult patient, guiding decision for surgical excision (90). Penget al reported the utility of PET imaging with alpha-[11C]methyl-L-tryptophan in assessing the treatment response in a child with symptomatic ONG (91). Mohariret al, in a small retrospective study of pediatric patients with NF-1, implied that 18F-FDG PET/CT may play a role in ONG surveillance by differentiating those tumors with a higher likelihood to advance and become symptomatic (92). Roselliet al reported the application of PET/CT with 18F-fluorocholine (18F-FCH), which targets the biosynthesis of cell membranes, in assessing treatment response of ONG in the setting of NF-1 (93). Rizzoet al, in a recent case report, described intense 11C-methionine (11C-MET) activity by an ONG in an 80-year-old male patient (94). 11C-MET, is a PET-tracer, targeting amino acid utilization processes, which exhibits advantages over 18F-FDG in detecting brain tumors, such as very low-level activity by inflammatory sites and by normal brain tissue (95). These data hold promise for the application of 11C-MET PET imaging in patients with ONG. However, larger prospective series of patients are required to elucidate the role of PET-imaging utilizing several PET-tracers beyond 18F-FDG in the management of both benign and malignant ONG types.

10. Ocular and orbital metastases

Intra-ocular metastases are the most common intra-ocular malignancy, and often the first sign of systemic cancer spreading (96). The uvea, due to its rich vascularity, is the commonest metastatic site with the choroid being the most often metastatic location, while iris or ciliary body involvement is less commonly encountered (97). In patients with presumed uveal metastases, conventional imaging modalities (CT and MRI) often fail to detect the primary tumor. In this setting of patients, whole-body 18F-FDG PET/CT studies can vitally contribute to accurate patient management, by successfully detecting the primary site and other metastatic lesions not seen on CT or MRI (98).

Orbital metastases stand for the most commonly encountered orbital malignancy, accounting for approximately 20% of all orbital cancers (36,99), and being the first disease manifestation in 15% of the cases (100). Patients with orbital metastases usually present with diplopia, pain, palpable mass, proptosis, strabismus and visual loss. Breast, lung and prostatic cancer, together with cutaneous melanoma and neuroblastomas in children are the commonest tumors metastasizing to the orbit (36,99,101). Orbital metastases exhibit 18F-FDG avidity and therefore, 18F-FDG PET/CT is a valuable diagnostic tool for these patients, enabling detection of the primary tumor, accurate disease staging and effective assessment of therapeutic response (99). Furthermore, orbital metastases originating from NETs can be successfully detected on SSTRs imaging with PET using 68Ga-DOTA-conjugated compounds (18,101). Both ocular and orbital metastases harbor histological features identical to the primary malignancy, and therefore, immunohistochemistry should be employed in challenging cases, where imaging with advanced hybrid techniques fails to detect the primary disease site.

11. Inflammatory orbital pseudotumor

Inflammatory orbital pseudotumor (IOP), also known as idiopathic orbital pseudotumor, is a benign, non-infective, inflammatory condition of the orbit without systematic or locally identifiable causes, being reported as the most common cause of painful orbital mass and the third most common orbital disease following thyroid orbitopathy and lymphoproliferative disorder (102,103). Typically, adult patients with IOP suffer from unilateral orbital pain, proptosis and impaired ocular movement, while in pediatric cohorts, IOP is bilaterally manifested, commonly associated with disc edema, uveitis and eosinophilia (103). Histopathologically, IOPs are characterized by a mixed inflammatory infiltrate, exhibiting a mixture of small lymphocytes, plasma cells and histiocytes (36,102), while fibrosis is frequently encountered (104).

Imaging-wise, IOP is a great 'mimicker’ (105). 18F-FDG PET/CT scans demonstrate highly elevated radiotracer activity, in a lymphoma-mimicking pattern and biopsy is further required for establishing diagnosis (36). However, 18F-FDG PET/CT can efficiently facilitate accurate monitoring of treatment response, in cases of non-surgical treatment approaches such as radiotherapy or administration of steroids, or in cases of incomplete surgical resection and lesion recurrence (106).

12. Fibrous dysplasia

Fibrous dysplasia (FD) of the bone is an uncommon, developmental benign skeletal disorder, characterized by the replacement of normal bone and normal bone marrow with abnormal fibro-osseous tissue, leading to bone deformity, pain, fractures and physical impairment (107). FD may affect a single skeletal site (monostotic FD), or multiple sites (polyostotic FD), and can be encountered either sporadically or in combination with extra-skeletal manifestations, including café-au-lait-like skin pigmentation and hyperfunctioning endocrinopathies. The combination of skeletal FD lesions with one or more extra-skeletal manifestations is termed McCune-Albright syndrome (MAS) (107,108). FD involvement of the orbital bones can lead to hypertelorism, exophthalmos, vision impairment or even vision loss, due to narrowing of the optic nerve canal and subsequent optic nerve compression (36). Typically, bone FD lesions present a characteristic ground-glass appearance on the CT scan with expansion of the medullary cavity (Fig. 6).

Bone FD lesions may present 18F-FDG-negative (109,110) or exhibit variable degrees of 18F-FDG activity on PET/CT, mimicking malignancy (111-116). However, co-registration with CT enables confident characterization of lesions and avoidance of erroneous interpretation of 18F-FDG positive skeletal findings. Moreover, intensely increasing 18F-FDG activity by FD lesions should raise suspicion for the rare possibility of malignant transformation (<2% of all FD cases) (117,118). In this particular setting of malignantly transformed FD lesions, whole-body 18F-FDG PET/CT has a role in the early detection of the transformation and in the management of these patients, by facilitating accurate biopsy guidance, staging, optimal surgical planning, detection of recurrence and efficient follow-up (118).

Bone FD has been visualized with conventional SSTRs scintigraphy using 111ln-pentetreotide, suggesting cell surface over-expression of SSTRs by fibrous dysplastic cells (119). The introduction of 68Ga-DOTA-conjugated-peptides into clinical practice has enabled the employment of PET-imaging in targeting lesions, characterized by SSTRs-overexpressi on (18,19-33). Papadakiset al reported intensely increased 68Ga-DOTATE (radiolabeled somatostatin analogue suitable for PET-imaging, which targets SSTRs) activity on PET/CT, by a biopsy proven FD lesion in the temporal bone (22). These data suggest the potential application of PET/CT with 68Ga-DOTA-conjugated-peptides in assessing and monitoring FD activity or even prognostic value of 68Ga-DOTATATE uptake in FD lesions that need to be further investigated. Furthermore, bone FD can be effectively targeted with 18F-NaF PET/CT (Fig. 7), which has been shown to be strongly associated with bone turnover markers in the blood, while exhibiting prognostic value for clinical manifestations of the disorder (120-124).

13. PET-MRI

PET/MRI combines the functional information of PET with the superior soft-tissue contrast and the functional MR-sequences, providing enhanced oncologic applications, especially in small anatomic regions with complex anatomy such as the orbital and ocular space. Furthermore, pediatric and pregnant oncologic patients with need for follow-up studies, can take advantage of the reduced radiation exposure of PET/MRI compared to PET/CT. In recent years, PET-MRI technology has evolved into an established clinical diagnostic tool, with instrumentation advancements leading to PET detectors compatible with the MRI field, enabling simultaneous PET and MRI acquisition (125,126). These advancements hold promise for superior diagnostic capabilities, improved image quality with reduced PET-image noise, more accurate co-registration of PET-data with MRI anatomy, correction for respiratory, heart and bulk patient motion, and temporal synchronization of the data acquired by the two modalities (4).

PET/MRI has already been widely employed in the management of head and neck cancers, providing incremental diagnostic information for the local staging of the primary tumor and regional lymph node status, while facilitating more accurate radiation treatment planning (4,36,127,128). Patients with lymphomas, neuroblastomas and soft tissue sarcomas may benefit from PET/MRI evaluation, which holds promise for improved oncologic applications (36,127-130), with further studies being needed in order to elucidate the role and the added value of this modality in ophthalmic oncology.

14. Conclusions

The introduction of hybrid PET/CT and PET/MRI systems into clinical practice has opened new broad horizons in ophthalmic oncology. The challenges of managing orbital and ocular tumors, can be addressed more effectively, through these multimodal imaging approaches. For the detection of primary orbital and ocular tumors, 18F-FDG PET/CT imaging does not seem to offer additional information over clinical evaluation and conventional anatomic imaging modalities (CT, MRI and US). However, 18F-FDG PET/CT has an established role for patients with OL and OAL both at initial staging and post-treatment assessment. In addition, despite contradictory data, patients with UM most likely will have significant benefit from evaluation with 18F-FDG PET/CT for staging and follow-up. Moreover, 18F-FDG PET/CT is of utmost value for patients presenting with intraocular or orbital metastases, and unknown primary cancer. For the remaining set of ophthalmic tumors, 18F-FDG PET/CT seems to be of value for advanced malignancies with an increased suspicion of regional or distant disease dissemination. PET/CT with 18F-NaF is the imaging modality of choice for the evaluation and monitoring of disease activity in patients with FD of the orbital bones. Finally, in patients with well-differentiated NETs, PET/CT using 68Ga-DOTA-compounds is the imaging technique of reference for detecting orbital or ocular metastases. The development of novel cancer-specific PET-tracers together with the advent of clinical simultaneous PET/MRI systems and the employment of artificial intelligence (AI)-based multi-modal predictive models (130), hold promise for more efficient personalized management strategies of ophthalmic oncology patients.

Funding

Part of this study was financially supported by the Stavros Niarchos Foundation within the framework of the project ARCHERS ('Advancing Young Researchers’ Human Capital in Cutting Edge Technologies in the Preservation of Cultural Heritage and the Tackling of Societal Challenges’).

Availability of data and materials

Not applicable.

Authors’ contributions

GZP and MSK conceived and designed the study. GZP and MSK researched the literature, performed analysis and interpretation of data and drafted the manuscript. AHK, DE, ETD, OZ, KM, CM, UB, IP, AS, IK KP, PK, GAK, DAS and AT critically revised the article for important intellectual content, and assisted in the literature search for this review article. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated, and finally approved the version of the manuscript to be published. IK also designed Fig. 1.

Ethics approval and consent to participate

The patient images presented in Figs. 2-7 were obtained after acquiring ethics approval from the relevant ethics committees and patient consent. The images in Figs. 2-6 were provided by the author DE, from the PET/CT department of Evangelismos Hospital in Athens; all patients have provided written consent forms prior to scanning. Fig. 7 was provided by esteemed physicians at the NIH, with whom the senior and corresponding author of the article collaborates. All study participants at the NIH clinical protocols provided all the extensive consent forms and strict ethical approval documents that the NIH standards require.

Patient consent for publication

Not applicable.

Competing interests

DAS is the Editor-in-Chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article. All the other authors declare that they have no competing interests.

Abbreviations:

EFS

event-free survival

OS

overall survival

AJCC

American Joint Cancer Committee

SUVmax

maximum standardized uptake value

OL

orbital lymphoma

OAL

ocular adnexal lymphoma

NHL

non-Hodgkin’s lymphoma

HL

Hodgkin’s lymphoma

UM

uveal melanoma

RB

retinoblastoma

CM

conjunctival melanoma

IOP

inflammatory orbital pseudotumor

18F-FDG

18fluoride-fludeoxyglucose

GLUT-1

glucose transporter-1

LN

lymph node

US

ultrasonography

PET

positron emission tomography

CT

computed tomography

PET/CT

positron emission tomography/computed tomography

MRI

magnetic resonance imaging

TNM

tumor-node-metastases

LFTs

liver function tests

PPV

positive predictive value

NPV

negative predictive value

HNSCC

head and neck squamous cell carcinoma

ONG

optic nerve glioma

OPG

optic pathway glioma

NF-1

neurofibromatosis type 1

CRVO

central retinal vein occlusion

18F-FCH

18F-fluorocholine

11C-MET

11C-methionine

FD

fibrous dysplasia

MAS

McCune-Albright syndrome

SSTRs

somatostatin receptors

Acknowledgments

Not applicable.

References

1 

Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA; European Association of Nuclear Medicine (EANM); et al: FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 42:328–354. 2015. View Article : Google Scholar :

2 

Pfannenberg AC, Aschoff P, Brechtel K, Müller M, Klein M, Bares R, Claussen CD and Eschmann SM: Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. Br J Radiol. 80:437–445. 2007. View Article : Google Scholar : PubMed/NCBI

3 

Bashir U, Mallia A, Stirling J, Joemon J, MacKewn J, Charles-Edwards G, Goh V and Cook GJ: PET/MRI in Oncological Imaging: State of the Art. Diagnostics (Basel). 5:333–357. 2015. View Article : Google Scholar

4 

Broski SM, Goenka AH, Kemp BJ and Johnson GB: Clinical PET/MRI: 2018 Update. AJR Am J Roentgenol. 211:295–313. 2018. View Article : Google Scholar : PubMed/NCBI

5 

Papadakis GZ, Manikis GC, Hannah-Shmouni F, O’Brien KJ, Gahl WA and Estrada-Veras JI: Higher metabolic activity seen on 18F-FDG PET/CT, in the adrenal glands of patients with Erdheim-Chester Disease harboring the BRAF V600E mutation. Pediatr Blood Cancer. 64(Suppl): S29. 2017.

6 

Papadakis GZ, Patronas NJ, Chen CC, Carney JA and Stratakis CA: Combined PET/CT by 18F-FDOPA, 18F-FDA, 18F-FDG, and MRI correlation on a patient with Carney triad. Clin Nucl Med. 40:70–72. 2015. View Article : Google Scholar

7 

Diker-Cohen T, Abraham SB, Rauschecker M, Papadakis GZ, Munir KM, Brown E, Lyssikatos C, Belyavskaya E, Merino M and Stratakis CA: Reninoma presenting in pregnancy. J Clin Endocrinol Metab. 99:2625–2626. 2014. View Article : Google Scholar : PubMed/NCBI

8 

Karageorgiadis AS, Papadakis GZ, Biro J, Keil MF, Lyssikatos C, Quezado MM, Merino M, Schrump DS, Kebebew E, Patronas NJ, et al: Ectopic adrenocorticotropic hormone and corticotropin-releasing hormone co-secreting tumors in children and adolescents causing cushing syndrome: A diagnostic dilemma and how to solve it. J Clin Endocrinol Metab. 100:141–148. 2015. View Article : Google Scholar :

9 

Hammoud DA, Boulougoura A, Papadakis GZ, Wang J, Dodd LE, Rupert A, Higgins J, Roby G, Metzger D, Laidlaw E, et al: Increased metabolic activity on 18F-Fluorodeoxyglucose positron emission tomography-computed tomography in human immunodeficiency virus-associated immune reconstitution inflammatory syndrome. Clin Infect Dis. 68:229–238. 2019. View Article : Google Scholar

10 

Hannah-Shmouni F, Papadakis GZ, Stratakis CA and Blau J: Enlarging hypermetabolic nodule: Benign non-functional adrenocortical adenoma. BMJ Case Rep. 2017:bcr20172208202017. View Article : Google Scholar

11 

Papadakis GZ, Millo C and Stratakis CA: Benign hormone-secreting adenoma within a larger adrenocortical mass showing intensely increased activity on 18F-FDG PET/CT. Endocrine. 54:269–270. 2016. View Article : Google Scholar : PubMed/NCBI

12 

Papadakis GZ, Holland SM, Quezado M and Patronas NJ: Adrenal cryptococcosis in an immunosuppressed patient showing intensely increased metabolic activity on 18F-FDG PET/CT. Endocrine. 54:834–836. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Papadakis GZ, Millo C, Bagci U, Patronas NJ and Stratakis CA: Talc pleurodesis with intense 18F-FDG activity but no 68Ga-DOTA-TATE activity on PET/CT. Clin Nucl Med. 40:819–820. 2015. View Article : Google Scholar : PubMed/NCBI

14 

Bastawrous S, Bhargava P, Behnia F, Djang DS and Haseley DR: Newer PET application with an old tracer: Role of 18F-NaF skeletal PET/CT in oncologic practice. Radiographics. 34:1295–1316. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Papadakis GZ, Jha S, Bhattacharyya T, Millo C, Tu TW, Bagci U, Marias K, Karantanas AH and Patronas NJ: 18F-NaF PET/CT in extensive melorheostosis of the axial and appendicular Skeleton With Soft-Tissue Involvement. Clin Nucl Med. 42:537–539. 2017. View Article : Google Scholar : PubMed/NCBI

16 

Papadakis GZ, Jha S, Karantanas AH, Marias K, Bagci U and Bhattacharyya T: Prospective evaluation of the application of 18F-NaF PET/CT imaging in melorheostosis. Eur J Nucl Med Mol Imaging. 45(Suppl 1): S231–S232. 2018.

17 

Papadakis GZ, Millo C, Bagci U, Blau J and Collins MT: 18F-NaF and 18F-FDG PET/CT in Gorham-Stout Disease. Clin Nucl Med. 41:884–885. 2016. View Article : Google Scholar : PubMed/NCBI

18 

Papadakis GZ, Millo C, Bagci U, Patronas NJ and Collins MT: Value of 18F-NaF PET/CT imaging in the assessment of Gorham-Stout disease activity. Eur J Nucl Med Mol Imaging. 43(Suppl 1): S597. 2016. View Article : Google Scholar

19 

Hofman MS, Lau WF and Hicks RJ: Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: Clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 35:500–516. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Tirosh A, Papadakis GZ, Millo C, Hammoud D, Sadowski SM, Herscovitch P, Pacak K, Marx SJ, Yang L, Nockel P, et al: Prognostic utility of total 68Ga-DOTATATE-avid tumor volume in patients with neuroendocrine tumors. Gastroenterology. 154:998–1008.e1. 2018. View Article : Google Scholar

21 

Tirosh A, Papadakis GZ, Millo C, Sadowski SM, Herscovitch P, Pacak K, Marx SJ, Yang L, Nockel P, Shell J, et al: Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements. Eur J Endocrinol. 176:575–582. 2017. View Article : Google Scholar : PubMed/NCBI

22 

Papadakis GZ, Millo C, Sadowski SM, Karantanas AH, Bagci U and Patronas NJ: Fibrous Dysplasia Mimicking Malignancy on 68Ga-DOTATATE PET/CT. Clin Nucl Med. 42:209–210. 2017. View Article : Google Scholar : PubMed/NCBI

23 

Papadakis GZ, Sadowski SM, Bagci U and Millo C: Application of 68Ga-DOTA-TATE PET/CT in metastatic neuroendocrine tumor of gastrointestinal origin. Ann Gastroenterol. 30:1302017.

24 

Papadakis GZ, Millo C, Jassel IS, Bagci U, Sadowski SM, Karantanas AH and Patronas NJ: 18F-FDG and 68Ga-DOTATATE PET/CT in von Hippel-Lindau disease-associated retinal heman-gioblastoma. Clin Nucl Med. 42:189–190. 2017. View Article : Google Scholar

25 

Papadakis GZ, Millo C, Karantanas AH, Bagci U and Patronas NJ: Avascular necrosis of the hips with increased activity on 68Ga-DOTATATE PET/CT. Clin Nucl Med. 42:214–215. 2017. View Article : Google Scholar :

26 

Papadakis GZ, Millo C, Sadowski SM, Karantanas AH, Bagci U and Patronas NJ: Breast fibroadenoma with increased activity on 68Ga DOTATATE PET/CT. Clin Nucl Med. 42:145–146. 2017. View Article : Google Scholar :

27 

Papadakis GZ, Millo C, Sadowski SM, Bagci U and Patronas NJ: Kidney Tumor in a von Hippel-Lindau (VHL) patient with intensely increased activity on 68Ga-DOTA-TATE PET/CT. Clin Nucl Med. 41:970–971. 2016. View Article : Google Scholar : PubMed/NCBI

28 

El-Maouche D, Sadowski SM, Papadakis GZ, Guthrie L, Cottle-Delisle C, Merkel R, Millo C, Chen CC, Kebebew E and Collins MT: 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab. 101:3575–3581. 2016. View Article : Google Scholar : PubMed/NCBI

29 

Papadakis GZ, Millo C, Sadowski SM, Bagci U and Patronas NJ: Epididymal cystadenomas in von Hippel-Lindau disease showing increased activity on 68Ga DOTATATE PET/CT. Clin Nucl Med. 41:781–782. 2016. View Article : Google Scholar : PubMed/NCBI

30 

Papadakis GZ, Millo C, Sadowski SM, Bagci U and Patronas NJ: Endolymphatic sac tumor showing increased activity on 68Ga-DOTATATE PET/CT. Clin Nucl Med. 41:783–784. 2016. View Article : Google Scholar : PubMed/NCBI

31 

Papadakis GZ, Millo C, Bagci U, Sadowski SM and Stratakis CA: Schmorl nodes can cause increased 68Ga-DOTATATE activity on PET/CT, mimicking metastasis in patients with neuroendocrine malignancy. Clin Nucl Med. 41:249–250. 2016. View Article : Google Scholar :

32 

Papadakis GZ, Bagci U, Sadowski SM, Patronas NJ and Stratakis CA: Ectopic ACTH and CRH co-secreting tumor localized by 68Ga-DOTA-TATE PET/CT. Clin Nucl Med. 40:576–578. 2015. View Article : Google Scholar : PubMed/NCBI

33 

Tirosh A, Papadakis GZ, Millo C, Sadowski SM, Herscovitch P, Pacak K, Marx SJ, Yang L, Nockel P, Shell J, et al: High total 68Ga-DOTATATE-Avid Tumor Volume (TV) is associated with low progression-free survival and high disease-specific mortality rate in patients with neuroendocrine tumors. Endocrine Abstracts. 49:OC7.32017.

34 

Honavar SG and Manjandavida FP: Recent Advances in Orbital Tumors - A Review of Publications from 2014-2016. Asia Pac J Ophthalmol (Phila). 6:153–158. 2017.

35 

Hui KH, Pfeiffer ML and Esmaeli B: Value of positron emission tomography/computed tomography in diagnosis and staging of primary ocular and orbital tumors. Saudi J Ophthalmol. 26:365–371. 2012. View Article : Google Scholar

36 

Purohit BS, Vargas MI, Ailianou A, Merlini L, Poletti PA, Platon A, Delattre BM, Rager O, Burkhardt K and Becker M: Orbital tumours and tumour-like lesions: Exploring the arma-mentarium of multiparametric imaging. Insights Imaging. 7:43–68. 2016. View Article : Google Scholar

37 

English JF and Sullivan TJ: The Role of FDG-PET in the diagnosis and staging of ocular adnexal lymphoproliferative disease. Orbit. 34:284–291. 2015. View Article : Google Scholar : PubMed/NCBI

38 

Valenzuela AA, Allen C, Grimes D, Wong D and Sullivan TJ: Positron emission tomography in the detection and staging of ocular adnexal lymphoproliferative disease. Ophthalmology. 113:2331–2337. 2006. View Article : Google Scholar : PubMed/NCBI

39 

Roe RH, Finger PT, Kurli M, Tena LB and Iacob CE: Whole-body positron emission tomography/computed tomography imaging and staging of orbital lymphoma. Ophthalmology. 113:1854–1858. 2006. View Article : Google Scholar : PubMed/NCBI

40 

Suga K, Yasuhiko K, Hiyama A, Takeda K and Matsunaga N: 18F-FDG PET/CT findings in a patient with bilateral orbital and gastric mucosa-associated lymphoid tissue lymphomas. Clin Nucl Med. 34:589–593. 2009. View Article : Google Scholar : PubMed/NCBI

41 

Gayed I, Eskandari MF, McLaughlin P, Pro B, Diba R and Esmaeli B: Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy. Ophthalmic Surg Lasers Imaging. 38:319–325. 2007. View Article : Google Scholar : PubMed/NCBI

42 

Sallak A, Besson FL, Pomoni A, Christinat A, Adler M, Aegerter JP, Nguyen C, de Leval L, Frossard V and Prior JO: Conjunctival MALT lymphoma: Utility of FDG PET/CT for diagnosis, staging, and evaluation of treatment response. Clin Nucl Med. 39:295–297. 2014. View Article : Google Scholar : PubMed/NCBI

43 

Yildirim-Poyraz N, Ozdemir E, Basturk A, Kilicarslan A and Turkolmez S: PET/CT findings in a case with FDG-avid disseminated lacrimal gland MALToma with sequential development of large B-cell lymphoma and gastric MALToma. Clin Nucl Med. 40:141–145. 2015. View Article : Google Scholar

44 

Fujii H, Tanaka H, Nomoto Y, Harata N, Oota S, Isogai J and Yoshida K: Usefulness of 18F-FDG PET/CT for evaluating response of ocular adnexal lymphoma to treatment. Medicine (Baltimore). 97:e05432018. View Article : Google Scholar

45 

Hu DN, Yu GP, McCormick SA, Schneider S and Finger PT: Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol. 140:612–617. 2005. View Article : Google Scholar : PubMed/NCBI

46 

Singh AD, Turell ME and Topham AK: Uveal melanoma: Trends in incidence, treatment, and survival. Ophthalmology. 118:1881–1885. 2011. View Article : Google Scholar : PubMed/NCBI

47 

Finger PT, Kurli M, Wesley P, Tena L, Kerr KR and Pavlick A: Whole body PET/CT imaging for detection of metastatic choroidal melanoma. Br J Ophthalmol. 88:1095–1097. 2004. View Article : Google Scholar : PubMed/NCBI

48 

Reddy S, Kurli M, Tena LB and Finger PT: PET/CT imaging: Detection of choroidal melanoma. Br J Ophthalmol. 89:1265–1269. 2005. View Article : Google Scholar : PubMed/NCBI

49 

Finger PT, Chin K and Iacob CE: 18-Fluorine-labelled 2 - deoxy-2 -fluoro - D – glucose positron emission tomography/computed tomography standardised uptake values: A non-invasive biomarker for the risk of metastasis from choroidal melanoma. Br J Ophthalmol. 90:1263–1266. 2006. View Article : Google Scholar : PubMed/NCBI

50 

Matsuo T, Ogino Y, Ichimura K, Tanaka T and Kaji M: Clinicopathological correlation for the role of fluorodeoxy-glucose positron emission tomography computed tomography in detection of choroidal malignant melanoma. Int J Clin Oncol. 19:230–239. 2014. View Article : Google Scholar

51 

McCannel TA, Reddy S, Burgess BL and Auerbach M: Association of positive dual-modality positron emission tomography/computed tomography imaging of primary choroidal melanoma with chromosome 3 loss and tumor size. Retina. 30:146–151. 2010. View Article : Google Scholar

52 

Papastefanou VP, Islam S, Szyszko T, Grantham M, Sagoo MS and Cohen VML: Metabolic activity of primary uveal melanoma on PET/CT scan and its relationship with monosomy 3 and other prognostic factors. Br J Ophthalmol. 98:1659–1665. 2014. View Article : Google Scholar : PubMed/NCBI

53 

Kurli M, Reddy S, Tena LB, Pavlick AC and Finger PT: Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma. Am J Ophthalmol. 140:193–199. 2005. View Article : Google Scholar : PubMed/NCBI

54 

Freton A, Chin KJ, Raut R, Tena LB, Kivelä T and Finger PT: Initial PET/CT staging for choroidal melanoma: AJCC correlation and second nonocular primaries in 333 patients. Eur J Ophthalmol. 22:236–243. 2012. View Article : Google Scholar

55 

Strobel K, Bode B, Dummer R, Veit-Haibach P, Fischer DR, Imhof L, Goldinger S, Steinert HC and von Schulthess GK: Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. Eur J Nucl Med Mol Imaging. 36:1774–1782. 2009. View Article : Google Scholar : PubMed/NCBI

56 

Orcurto V, Denys A, Voelter V, Schalenbourg A, Schnyder P, Zografos L, Leyvraz S, Delaloye AB and Prior JO: (18) F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: Results from a pilot study. Melanoma Res. 22:63–69. 2012. View Article : Google Scholar

57 

Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL and Bunin GR: Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995. (NIH Pub No 99-4649). National Cancer Institute; Bethesda, MD: 1999

58 

Jakobiec FA, Tso MO, Zimmerman LE and Danis P: Retinoblastoma and intracranial malignancy. Cancer. 39:2048–2058. 1977. View Article : Google Scholar : PubMed/NCBI

59 

de Jong MC, Kors WA, de Graaf P, Castelijns JA, Kivelä T and Moll AC: Trilateral retinoblastoma: A systematic review and meta-analysis. Lancet Oncol. 15:1157–1167. 2014. View Article : Google Scholar : PubMed/NCBI

60 

Kamihara J, Bourdeaut F, Foulkes WD, Molenaar JJ, Mossé YP, Nakagawara A, Parareda A, Scollon SR, Schneider KW, Skalet AH, et al: Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clin Cancer Res. 23:e98-e1062017. View Article : Google Scholar : PubMed/NCBI

61 

Yamanaka R, Hayano A and Takashima Y: Trilateral retinoblastoma: A systematic review of 211 cases. Neurosurg Rev. 42:39–48. 2019. View Article : Google Scholar

62 

Honavar SG, Manjandavida FP and Reddy VAP: Orbital retinoblastoma: An update. Indian J Ophthalmol. 65:435–442. 2017. View Article : Google Scholar : PubMed/NCBI

63 

Radhakrishnan V, Kumar R, Malhotra A and Bakhshi S: Role of PET/CT in staging and evaluation of treatment response after 3 cycles of chemotherapy in locally advanced retinoblastoma: A prospective study. J Nucl Med. 53:191–198. 2012. View Article : Google Scholar : PubMed/NCBI

64 

Yu GP, Hu DN, McCormick S and Finger PT: Conjunctival melanoma: Is it increasing in the United States? Am J Ophthalmol. 135:800–806. 2003. View Article : Google Scholar : PubMed/NCBI

65 

Folberg R, McLean IW and Zimmerman LE: Malignant melanoma of the conjunctiva. Hum Pathol. 16:136–143. 1985. View Article : Google Scholar : PubMed/NCBI

66 

Damian A, Gaudiano J, Engler H and Alonso O: (18)F-FDG PET-CT for Staging of Conjunctival Melanoma. World J Nucl Med. 12:45–47. 2013. View Article : Google Scholar : PubMed/NCBI

67 

Tuomaala S and Kivelä T: Metastatic pattern and survival in disseminated conjunctival melanoma: Implications for sentinel lymph node biopsy. Ophthalmology. 111:816–821. 2004. View Article : Google Scholar : PubMed/NCBI

68 

Kurli M, Chin K and Finger PT: Whole-body 18 FDG PET/CT imaging for lymph node and metastatic staging of conjunctival melanoma. Br J Ophthalmol. 92:479–482. 2008. View Article : Google Scholar : PubMed/NCBI

69 

Tsai SY, Shiau YC, Wang SY and Wu YW: Conjunctival Melanoma on 18F-FDG PET/CT as a Second Primary Cancer. Clin Nucl Med. 41:237–238. 2016. View Article : Google Scholar

70 

Muqit MM, Foot B, Walters SJ, Mudhar HS, Roberts F and Rennie IG: Observational prospective cohort study of patients with newly-diagnosed ocular sebaceous carcinoma. Br J Ophthalmol. 97:47–51. 2013. View Article : Google Scholar

71 

Yin VT, Merritt HA, Sniegowski M and Esmaeli B: Eyelid and ocular surface carcinoma: Diagnosis and management. Clin Dermatol. 33:159–169. 2015. View Article : Google Scholar : PubMed/NCBI

72 

Shields JA, Demirci H, Marr BP, Eagle RC Jr and Shields CL: Sebaceous carcinoma of the eyelids: Personal experience with 60 cases. Ophthalmology. 111:2151–2157. 2004. View Article : Google Scholar : PubMed/NCBI

73 

Baek CH, Chung MK, Jeong HS, Son YI, Choi J, Kim YD, Choi JY, Kim HJ and Ko YH: The clinical usefulness of (18) F-FDG PET/CT for the evaluation of lymph node metastasis in periorbital malignancies. Korean J Radiol. 10:1–7. 2009. View Article : Google Scholar : PubMed/NCBI

74 

Krishna SM, Finger PT, Chin K and Lacob CE: 18-FDG PET/CT staging of ocular sebaceous cell carcinoma. Graefes Arch Clin Exp Ophthalmol. 245:759–760. 2007. View Article : Google Scholar : PubMed/NCBI

75 

Ishiguro Y, Homma S, Yoshida T, Ohno Y, Ichikawa N, Kawamura H, Hata H, Kase S, Ishida S, Okada-Kanno H, et al: Usefulness of PET/CT for early detection of internal malignancies in patients with Muir-Torre syndrome: Report of two cases. Surg Case Rep. 3:712017. View Article : Google Scholar : PubMed/NCBI

76 

Faustina M, Diba R, Ahmadi MA and Esmaeli B: Patterns of regional and distant metastasis in patients with eyelid and peri-ocular squamous cell carcinoma. Ophthalmology. 111:1930–1932. 2004. View Article : Google Scholar : PubMed/NCBI

77 

Donaldson MJ, Sullivan TJ, Whitehead KJ and Williamson RM: Squamous cell carcinoma of the eyelids. Br J Ophthalmol. 86:1161–1165. 2002. View Article : Google Scholar : PubMed/NCBI

78 

Soysal HG and Markoç F: Invasive squamous cell carcinoma of the eyelids and periorbital region. Br J Ophthalmol. 91:325–329. 2007. View Article : Google Scholar

79 

Reifler DM and Hornblass A: Squamous cell carcinoma of the eyelid. Surv Ophthalmol. 30:349–365. 1986. View Article : Google Scholar : PubMed/NCBI

80 

Yi JS, Kim JS, Lee JH, Choi SH, Nam SY, Kim SY and Roh JL: 18F-FDG PET/CT for detecting distant metastases in patients with recurrent head and neck squamous cell carcinoma. J Surg Oncol. 106:708–712. 2012. View Article : Google Scholar : PubMed/NCBI

81 

Lin LF, Chang CY and Cherng SC: Advanced squamous cell carcinoma of the bulbar conjunctiva seen on PET/CT. Clin Nucl Med. 33:929–930. 2008. View Article : Google Scholar : PubMed/NCBI

82 

Abdelmalik AG, Fajnwaks P, Osman MM and Nguyen NC: Squamous cell carcinoma of the bulbar conjunctiva seen on F-18 FDG PET/CT. Clin Nucl Med. 35:962–964. 2010. View Article : Google Scholar

83 

Jurdy L, Merks JHM, Pieters BR, Mourits MP, Kloos RJ, Strackee SD and Saeed P: Orbital rhabdomyosarcomas: A review. Saudi J Ophthalmol. 27:167–175. 2013. View Article : Google Scholar : PubMed/NCBI

84 

Norman G, Fayter D, Lewis-Light K, Chisholm J, McHugh K, Levine D, Jenney M, Mandeville H, Gatz S and Phillips B: An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: Systematic review. BMJ Open. 5:e0060302015. View Article : Google Scholar : PubMed/NCBI

85 

Harrison DJ, Parisi MT and Shulkin BL: The Role of 18F-FDG-PET/CT in Pediatric Sarcoma. Semin Nucl Med. 47:229–241. 2017. View Article : Google Scholar : PubMed/NCBI

86 

Teixeira SR, Martinez-Rios C, Hu L and Bangert BA: Clinical applications of pediatric positron emission tomography-magnetic resonance imaging. Semin Roentgenol. 49:353–366. 2014. View Article : Google Scholar : PubMed/NCBI

87 

Nair AG, Pathak RS, Iyer VR and Gandhi RA: Optic nerve glioma: An update. Int Ophthalmol. 34:999–1005. 2014. View Article : Google Scholar : PubMed/NCBI

88 

Becker M, Masterson K, Delavelle J, Viallon M, Vargas MI and Becker CD: Imaging of the optic nerve. Eur J Radiol. 74:299–313. 2010. View Article : Google Scholar : PubMed/NCBI

89 

Campen CJ and Gutmann DH: Optic Pathway Gliomas in Neurofibromatosis Type 1. J Child Neurol. 33:73–81. 2018. View Article : Google Scholar

90 

Miyamoto J, Sasajima H, Owada K and Mineura K: Surgical decision for adult optic glioma based on [18F]fluorodeoxy-glucose positron emission tomography study. Neurol Med Chir (Tokyo). 46:500–503. 2006. View Article : Google Scholar

91 

Peng F, Juhasz C, Bhambhani K, Wu D, Chugani DC and Chugani HT: Assessment of progression and treatment response of optic pathway glioma with positron emission tomography using alpha-[(11)C]methyl-L-tryptophan. Mol Imaging Biol. 9:106–109. 2007. View Article : Google Scholar : PubMed/NCBI

92 

Moharir M, London K, Howman-Giles R and North K: Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1. Eur J Nucl Med Mol Imaging. 37:1309–1317. 2010. View Article : Google Scholar : PubMed/NCBI

93 

Roselli F, Pisciotta NM, Aniello MS, Niccoli-Asabella A, Defazio G, Livrea P and Rubini G: Brain F-18 Fluorocholine PET/CT for the assessment of optic pathway glioma in neurofi-bromatosis-1. Clin Nucl Med. 35:838–839. 2010. View Article : Google Scholar : PubMed/NCBI

94 

Rizzo V, Mattoli MV, Trevisi G, Coli A, Calcagni ML and Montano N: Optic nerve glioblastoma detected by 11C-Methionine brain PET/CT. Rev Esp Med Nucl Imagen Mol. 37:259–260. 2018.

95 

Nakajima R, Kimura K, Abe K and Sakai S: 11C-methionine PET/CT findings in benign brain disease. Jpn J Radiol. 35:279–288. 2017. View Article : Google Scholar : PubMed/NCBI

96 

Konstantinidis L and Damato B: Intraocular Metastases - A Review. Asia Pac J Ophthalmol (Phila). 6:208–214. 2017.

97 

Konstantinidis L, Rospond-Kubiak I, Zeolite I, Heimann H, Groenewald C, Coupland SE and Damato B: Management of patients with uveal metastases at the Liverpool Ocular Oncology Centre. Br J Ophthalmol. 98:92–98. 2014. View Article : Google Scholar

98 

Donaldson MJ, Pulido JS, Mullan BP, Inwards DJ, Cantrill H, Johnson MR and Han MK: Combined positron emission tomography/computed tomography for evaluation of presumed choroidal metastases. Clin Exp Ophthalmol. 34:846–851. 2006. View Article : Google Scholar : PubMed/NCBI

99 

Shields JA, Shields CL and Scartozzi R: Survey of 1264 patients with orbital tumors and simulating lesions: The 2002 Montgomery Lecture, part 1. Ophthalmology. 111:997–1008. 2004. View Article : Google Scholar : PubMed/NCBI

100 

Valenzuela AA, Archibald CW, Fleming B, Ong L, O’Donnell B, Crompton JJ, Selva D, McNab AA and Sullivan TJ: Orbital metastasis: Clinical features, management and outcome. Orbit. 28:153–159. 2009. View Article : Google Scholar : PubMed/NCBI

101 

Das S, Pineda G, Goff L, Sobel R, Berlin J and Fisher G: The eye of the beholder: Orbital metastases from midgut neuroendocrine tumors, a two institution experience. Cancer Imaging. 18:472018. View Article : Google Scholar : PubMed/NCBI

102 

Ding ZX, Lip G and Chong V: Idiopathic orbital pseudotumour. Clin Radiol. 66:886–892. 2011. View Article : Google Scholar : PubMed/NCBI

103 

Weber AL, Romo LV and Sabates NR: Pseudotumor of the orbit. Clinical, pathologic, and radiologic evaluation. Radiol Clin North Am. 37:151–168. xi1999. View Article : Google Scholar : PubMed/NCBI

104 

Pakdaman MN, Sepahdari AR and Elkhamary SM: Orbital inflammatory disease: Pictorial review and differential diagnosis. World J Radiol. 6:106–115. 2014. View Article : Google Scholar : PubMed/NCBI

105 

Patnana M, Sevrukov AB, Elsayes KM, Viswanathan C, Lubner M and Menias CO: Inflammatory pseudotumor: The great mimicker. AJR Am J Roentgenol. 198:W217–27. 2012. View Article : Google Scholar : PubMed/NCBI

106 

Alongi F, Bolognesi A, Samanes Gajate AM, Motta M, Landoni C, Berardi G, Alongi P, Gianolli L and Di Muzio N: Inflammatory pseudotumor of mediastinum treated with tomotherapy and monitored with FDG-PET/CT: Case report and literature review. Tumori. 96:322–326. 2010. View Article : Google Scholar : PubMed/NCBI

107 

Boyce AM, Florenzano P, de Castro LF, Collins MT, Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K and Amemiya A: Fibrous Dysplasia/McCune-Albright Syndrome In: GeneReviews® [Internet]. University of Washington; Seattle, WA: 1993-2019

108 

Collins MT, Kushner H, Reynolds JC, Chebli C, Kelly MH, Gupta A, Brillante B, Leet AI, Riminucci M, Robey PG, et al: An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res. 20:219–226. 2005. View Article : Google Scholar : PubMed/NCBI

109 

Toba M, Hayashida K, Imakita S, Fukuchi K, Kume N, Shimotsu Y, Cho I, Ishida Y, Takamiya M and Kumita S: Increased bone mineral turnover without increased glucose utilization in sclerotic and hyperplastic change in fibrous dysplasia. Ann Nucl Med. 12:153–155. 1998. View Article : Google Scholar : PubMed/NCBI

110 

Shigesawa T, Sugawara Y, Shinohara I, Fujii T, Mochizuki T and Morishige I: Bone metastasis detected by FDG PET in a patient with breast cancer and fibrous dysplasia. Clin Nucl Med. 30:571–573. 2005. View Article : Google Scholar : PubMed/NCBI

111 

Stegger L, Juergens KU, Kliesch S, Wormanns D and Weckesser M: Unexpected finding of elevated glucose uptake in fibrous dysplasia mimicking malignancy: Contradicting metabolism and morphology in combined PET/CT. Eur Radiol. 17:1784–1786. 2007. View Article : Google Scholar

112 

Su MG, Tian R, Fan QP, Tian Y, Li FL, Li L, Kuang AR and Miller JH: Recognition of fibrous dysplasia of bone mimicking skeletal metastasis on 18F-FDG PET/CT imaging. Skeletal Radiol. 40:295–302. 2011. View Article : Google Scholar

113 

D’Souza MM, Jaimini A, Khurana A, Tripathi M, Sharma R, Mondal A and Srivastava M: Polyostotic fibrous dysplasia on F-18 FDG PET/CT imaging. Clin Nucl Med. 34:359–361. 2009. View Article : Google Scholar

114 

Kim M, Kim HS, Kim JH, Jang JH, Chung KJ, Shin MK, Hwang HS, Kim BC and Jung SY: F-18 FDG PET-positive fibrous dysplasia in a patient with intestinal non-Hodgkin’s lymphoma. Cancer Res Treat. 41:171–174. 2009. View Article : Google Scholar : PubMed/NCBI

115 

Choi YY, Kim JY and Yang SO: PET/CT in benign and malignant musculoskeletal tumors and tumor-like conditions. Semin Musculoskelet Radiol. 18:133–148. 2014. View Article : Google Scholar : PubMed/NCBI

116 

Kamaleshwaran KK, Joseph J, Kalarikal R and Shinto AS: Image Findings of Polyostotic Fibrous Dysplasia Mimicking Metastasis in F-18 FDG Positron Emission Tomography/Computed Tomography. Indian J Nucl Med. 32:137–139. 2017. View Article : Google Scholar : PubMed/NCBI

117 

Ruggieri P, Sim FH, Bond JR and Unni KK: Malignancies in fibrous dysplasia. Cancer. 73:1411–1424. 1994. View Article : Google Scholar : PubMed/NCBI

118 

Wei WJ, Sun ZK, Shen CT, Zhang XY, Tang J, Song HJ, Qiu ZL and Luo QY: Value of 99mTc-MDP SPECT/CT and 18F-FDG PET/CT scanning in the evaluation of malignantly transformed fibrous dysplasia. Am J Nucl Med Mol Imaging. 7:92–104. 2017.

119 

Chen CC, Czerwiec FS and Feuillan PP: Visualization of fibrous dysplasia during somatostatin receptor scintigraphy. J Nucl Med. 39:238–240. 1998.PubMed/NCBI

120 

Papadakis GZ, Manikis GC, Karantanas AH, Florenzano P, Bagci U, Marias K, Collins MT and Boyce AM: 18F-NaF PET/CT imaging in fibrous dysplasia of bone. J Bone Miner Res. 34:1619–1631. 2019. View Article : Google Scholar : PubMed/NCBI

121 

Papadakis G, Manikis G, Karantanas A, Marias K, Bagci U, Florenzano P, Collins M and Boyce A: Fibrous dysplasia related 18F-NaF activity in the spine is significantly higher in patients with scoliosis, compared to patients without spinal deformity. J Nucl Med. 60(Suppl 1): 1298S. 2019.

122 

Papadakis G, Manikis G, Karantanas A, Marias K, Bagci U, Florenzano P, Collins M and Boyce A: Positive Association between Fibrous Dysplasia (FD) related 18F-NaF activity and Bone Turnover Markers (BTMs). J Nucl Med. 60(Suppl 1): 90S. 2019.

123 

Papadakis G, Manikis G, Karantanas A, Marias K, Collins M and Boyce A: Application of 18F-NaF PET/CT imaging in prognosis of fractures and treatment planning in patients with fibrous dysplasia. J Nucl Med. 58(Suppl 1): 308S. 2017.

124 

Papadakis GZ, Manikis GC, Karantanas AH, Marias K, Collins MT and Boyce AM: Application of 18F-NaF PET/CT imaging in fibrous dysplasia. Horm Res Paediatr. 88(Suppl 1): 20. 2017.

125 

Delso G, Fürst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, Schwaiger M and Ziegler SI: Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med. 52:1914–1922. 2011. View Article : Google Scholar : PubMed/NCBI

126 

Levin CS, Maramraju SH, Khalighi MM, Deller TW, Delso G and Jansen F: Design features and mu-tual compatibility studies of the time-of-flight PET capable GE SIGNA PET/MR system. IEEE Trans Med Imaging. 35:1907–1914. 2016. View Article : Google Scholar : PubMed/NCBI

127 

Partovi S, Kohan A, Rubbert C, Vercher-Conejero JL, Gaeta C, Yuh R, Zipp L, Herrmann KA, Robbin MR, Lee Z, et al: Clinical oncologic applications of PET/MRI: A new horizon. Am J Nucl Med Mol Imaging. 4:202–212. 2014.PubMed/NCBI

128 

Varoquaux A, Rager O, Poncet A, Delattre BM, Ratib O, Becker CD, Dulguerov P, Dulguerov N, Zaidi H and Becker M: Detection and quantification of focal uptake in head and neck tumours: (18)F-FDG PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging. 41:462–475. 2014. View Article : Google Scholar

129 

Platzek I, Beuthien-Baumann B, Langner J, Popp M, Schramm G, Ordemann R, Laniado M, Kotzerke J and van den Hoff J: PET/MR for therapy response evaluation in malignant lymphoma: Initial experience. MAGMA. 26:49–55. 2013. View Article : Google Scholar :

130 

Papadakis GZ, Karantanas AH, Tsiknakis M, Tsatsakis A, Spandidos DA and Marias K: Deep learning opens new horizons in personalized medicine. Biomed Rep. 10:215–217. 2019.PubMed/NCBI

Related Articles

Journal Cover

February-2020
Volume 56 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kalemaki MS, Karantanas AH, Exarchos D, Detorakis ET, Zoras O, Marias K, Millo C, Bagci U, Pallikaris I, Stratis A, Stratis A, et al: PET/CT and PET/MRI in ophthalmic oncology (Review). Int J Oncol 56: 417-429, 2020
APA
Kalemaki, M.S., Karantanas, A.H., Exarchos, D., Detorakis, E.T., Zoras, O., Marias, K. ... Papadakis, G.Z. (2020). PET/CT and PET/MRI in ophthalmic oncology (Review). International Journal of Oncology, 56, 417-429. https://doi.org/10.3892/ijo.2020.4955
MLA
Kalemaki, M. S., Karantanas, A. H., Exarchos, D., Detorakis, E. T., Zoras, O., Marias, K., Millo, C., Bagci, U., Pallikaris, I., Stratis, A., Karatzanis, I., Perisinakis, K., Koutentakis, P., Kontadakis, G. A., Spandidos, D. A., Tsatsakis, A., Papadakis, G. Z."PET/CT and PET/MRI in ophthalmic oncology (Review)". International Journal of Oncology 56.2 (2020): 417-429.
Chicago
Kalemaki, M. S., Karantanas, A. H., Exarchos, D., Detorakis, E. T., Zoras, O., Marias, K., Millo, C., Bagci, U., Pallikaris, I., Stratis, A., Karatzanis, I., Perisinakis, K., Koutentakis, P., Kontadakis, G. A., Spandidos, D. A., Tsatsakis, A., Papadakis, G. Z."PET/CT and PET/MRI in ophthalmic oncology (Review)". International Journal of Oncology 56, no. 2 (2020): 417-429. https://doi.org/10.3892/ijo.2020.4955